Publications by authors named "Claudia Spohn"
Article Synopsis
- The study investigates the immune responses of patients with blood cancers receiving checkpoint-inhibitors after vaccination against SARS-CoV-2, comparing their outcomes with those of healthy controls.
- Results showed that while initial seroconversion (antibody response) was lower in patients (68%) compared to controls (98%), there was a significant improvement by day 120 across all patient groups, particularly for those on checkpoint-inhibitors.
- The research highlights that despite some patients showing T-cell responses, there was no clear link between antibody levels and T-cell responses, suggesting that evaluating both immune responses is important for understanding patient immunity and guiding public health vaccination strategies.
Introduction: The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML).
Method: After testing and a phase I study ( = 20), 59 patients were randomized in the IM/HU and 29 in the IM arm. According to protocol, 49 propensity-score matched IM patients were included from the CML-IV study.